T·Time Launches Cash-Pay Compounded GLP-1 and GIP Injections With Flat Pricing

Austin, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- T·Time Health Inc., the telehealth brand at ttime.men, has launched cash-pay compounded injectable semaglutide and tirzepatide with one published rate regardless of prescribed dose.

Compounded semaglutide is $99 per month ($297 billed quarterly), and compounded tirzepatide is $149 per month ($447 billed quarterly). The price includes medication, physician review, follow-up visits, 24/7 medical support, and next-day cold shipping, with no membership fee or additional required cost.

The same rate applies whether a clinician prescribes a starter dose, increases the dose during titration, or later adjusts treatment.

The launch is aimed in part at patients who need ongoing treatment after achieving a satisfactory result. STEP 4 and SURMOUNT-4 both documented substantial weight regain after treatment withdrawal.

According to T·Time’s October 2026 comparison of published ongoing all-in cash prices, including required membership, visit fees, and shipping, T·Time’s rates are approximately 40% to 80% lower than major national compounded-injection programs on their best prepaid plans.

T·Time also offers oral enclomiphene, sublingual sermorelin, and OVERTIME, a compounded vardenafil-tadalafil troche.

The compounded injections are prepared by a licensed U.S. compounding pharmacy after physician review and prescription. They are not Wegovy, Ozempic, Zepbound, or Mounjaro, and are not FDA-approved finished drugs. Patients who are not medically approved are refunded.

Learn more:https://ttime.men/glp-1

Sources

1. Wilding JPH, et al. STEP 4. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
2. Aronne LJ, et al. SURMOUNT-4. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
3. T·Time market comparison, October 2026.

About T·Time Health Inc.

T·TIME Health, Inc. is a Texas-based telehealth company providing access to prescription treatments through licensed U.S. medical providers and compounding pharmacies. Current treatment programs include enclomiphene, sermorelin, low-dose naltrexone, semaglutide, and tirzepatide.

Media Contact
Company Name: T·Time Health Inc.
Contact Person: Moshe Saraf
Email: press@ttime.men
Country: United States
Website: https://ttime.men

Disclaimer: Compounded medications are not FDA-approved finished drug products. Eligibility and treatment decisions are determined by a licensed clinician. Nothing in this release is medical advice.

The expert opinions presented in this PR/Story are based on the extensive experience and knowledge of the source company. These views do not necessarily reflect the opinions of the news distribution company and its distribution partners. There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any medical treatment, product, or service in this article. Moreover, nothing contained in this should be construed as medical advice or a recommendation to start, stop, or change any medical treatment or medication. It is your responsibility to determine whether any medical treatment, product, or service is appropriate for you based on your health objectives, medical condition, and risk tolerance. Consult your healthcare provider regarding your specific medical situation. The news distribution company and its distribution partners do not endorse or guarantee the accuracy, completeness, or reliability of the information shared by the guest. Viewers are encouraged to consult with their own healthcare professionals or conduct their own research when making decisions related to medical topics. The source company is the one issuing this release. Please contact them directly for further information.

Media Contact
Company Name: T·Time Health Inc.
Contact Person: Moshe Saraf
Email: press@ttime.men
Country: United States
Website: https://ttime.men